

Annual Shareholder's Meeting of SCHOTT Pharma AG & Co. KGaA on March 14, 2024

Proposal by the personally liable partner on appropriation of the net retained profit

The personally liable partner proposes utilizing the net retained profit of € 50.052.476,32 € from the annual financial statements of SCHOTT Pharma AG & Co. KGaA as of September 30, 2023, as follows:

Distribution of a dividend of € 0,15 for each share entitled to a dividend	€ 22.592.192,40
Net profit brought forward	€ 27.460.283,92
Net retained profit	€ 50.052.476,32

Mainz, January 2024

The personally liable partner
SCHOTT Pharma Management AG
The Executive Board



Andreas Reisse



Dr. Almuth Steinkühler